Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT02349191
Other study ID # Cottam - 1
Secondary ID
Status Not yet recruiting
Phase N/A
First received January 12, 2015
Last updated March 21, 2016
Start date March 2016
Est. completion date May 2019

Study information

Verified date March 2016
Source Bariatric Medicine Institute, Salt Lake City, UT
Contact Daniel Cottam, MD
Phone 8014196072
Email drdanielcottam@yahoo.com
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

This study is a prospective, single arm, non-randomized, interventional study to evaluate the safety and effectiveness of Omental transposition (OT) in subjects with early stage AD.

Within-subjects (repeated-measures) design will be utilized to compare follow-up outcomes to baseline.

The following assessments will be performed at baseline, then at 1, 3, 6, 12, and 24 months following surgery:

- Montreal Cognitive Assessment (MoCA)

- Alzheimer's Disease Assessment Scale-Cognition (ADAS-Cog)

- General Practitioner Assessment of Cognition (GPCOG)

- Eight-item Informant Interview to Differentiate Aging and Dementia (AD8) Subjects who have early stage AD confirmed by a neuropsychological test (MoCA) and who are healthy enough to undergo surgery.

The experimental procedure to be performed is omental transposition (OT) surgery. It will be performed as a laparoscopic or open procedure for omental lengthening and an open procedure for brain access, with a general surgeon performing the omental lengthening/tunneling and a neurosurgeon performing brain access/brain biopsy/omental placement on brain.

Up to twenty-five (25) subjects, with the first 5 subjects being part of a learning curve group and the next 20 subjects being part of the experimental group.

The duration of each subject's participation will be approximately 25 months from screening through the 24 month follow-up visit.


Description:

The experimental procedure to be performed is omental transposition surgery, during which a general surgeon and a neurosurgeon work as a team to transpose a pedicle omental graft to the surface of the brain. The general surgeon is responsible for performing a laparotomy/laparoscopy, elongating the omentum into a long pedicle and developing an extensive subcutaneous tunnel up the chest and neck to the head. The neurosurgeon is responsible for performing the craniotomy and securing the omentum on the brain.

Creating an intact omental pedicled flap requires the services of a general surgeon and neurosurgeon. The first step in the operation is to obtain access to the abdominal cavity laparoscopically using four 5cm trocars, or via laparotomy through an upper midline incision. The omentum is then removed from the transverse colon, after which it is separated from its proximal and central attachments to the stomach. The omentum detachments are made directly on the greater curvature of the stomach, leaving the gastroepiploic arteries and veins within the still-connected omentum apron.

Final separation of the omentum from the proximal portion of the stomach is done by dividing the left gastroepiploic vessels, which at the highest proximal level on the stomach become the short gastric vessels. The vascular connections to and from the omentum are now maintained solely from the right gastric and right gastroepiploic vessels. In order for the omental pedicle graft to reach the brain without tension, further surgical tailoring of the omentum is carried out, with care being taken to ensure the preservation of a major omental artery and vein.

After the omentum has been lengthened to an appropriate extent to reach the head, several small (3- to 4-inch) transverse incisions are made on the chest wall slightly lateral to the midline, with the side of the midline to make the transverse incisions depending on which cerebral hemisphere the omentum is to be placed. These transverse incisions are connected subcutaneously, thus creating a tunnel that begins at the upper pole of the midline abdominal incision and travels subcutaneously, up the chest wall and neck to behind the ear.

Although the subcutaneous tissue behind the ear is extremely dense, it is essential that the tunnel at this location be at least 2-3 finger lengths in width so that there is no constriction on the omentum in this particular area within the tunnel. As the omentum in the tunnel passes behind the ear, it goes beneath the base of the scalp flap that had been previously dissected in making the initial craniotomy incision.

The neurosurgery portion of the operation involves removal of a single piece of bone over the temporal-frontal area, opening the dura mater, followed by the removal of patches of arachnoid membrane, with care being taken to avoid blood vessels on the surface of the brain.

At this point in the operation, the omentum is laid directly upon the parietal-temporal-frontal area, after which the dura mater is sutured to the omentum. It is not necessary that the edges of the omentum be applied to the cut edges of the dura since the omentum can be tucked under the edges of the dura for greater coverage of the brain. The edges of the dura are then sewn to the top surface of the omentum using absorbable sutures and the craniotomy is closed.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 25
Est. completion date May 2019
Est. primary completion date April 2017
Accepts healthy volunteers No
Gender Both
Age group 65 Years to 85 Years
Eligibility Inclusion Criteria:

1. Male or female subjects between 60 to 85 years of age

2. Montreal Cognitive Assessment (MoCA) score of 11 to 18 (mild AD)

3. Healthy enough to undergo the surgical procedure based on surgical risk factor definitions (ASA = 3, using the ASA classification)

4. Must be able to read and understand English in order to complete all AD assessments

5. All medical illnesses other than dementia must be well controlled

6. Must have legally authorized caregiver if incapable of making their own decisions who is willing and able to perform the following:

1. provide informed consent if the subject is unable to do so;

2. monitor the subject;

3. answer informant based questionnaires;

4. provide transportation and accompany the subject to all visits

7. Subject or caregiver is willing and able to provide written informed consent and assent (if applicable)

8. Subject and/or caregiver are willing to comply with the study procedures and complete the entire study as specified in the protocol

Exclusion Criteria:

1. Life expectancy < 2 years

2. Subject who had or has cancer and is undergoing cancer therapy

3. Previous course of abdominal, cranial or neck radiotherapy or chemotherapy

4. Patients with neck calcifications may be excluded

5. Subject with uncontrolled heart disease, renal disease, or liver disease

6. Subject with diabetes mellitus whose glycoslated Hb (A1C) > 7

7. Complete blood count (CBC) with white blood cell <4,000 or platelets >125,000

8. Subject with uncontrollable hypertension (HTN)

9. Subject with previous abdominal surgery or disorder that could negatively influence the outcome of the OT surgery

10. Subject who has had a craniotomy in the past

11. Recent major surgery within the past 6 months

12. Use of cholinesterase inhibitors within the last 30 days and inability to not take cholinesterase inhibitors throughout the length of the study (about 25 mos)

13. Subject uses non-prescribed drugs of abuse or has a history of drug or alcohol abuse/dependence

14. Use of anticoagulants other then anti-platelet medications

15. Subject has significant central nervous system (CNS) disorder other than Alzheimer's disease

16. Subject has clinical evidence or history of stroke, transient ischemic attack, significant head injury or other unexplained or recurrent loss of consciousness =15 minutes

17. Major depressive disorder, schizophrenia, other psychotic disorders, or bipolar disorder

18. Subject has epilepsy

19. Patients with severe extra pyramidal signs

20. Patients with plastic surgery of the neck or face

21. Subject resides in hospital or moderate to high dependency continuous care facility

22. Non-English speaking subjects and/or caregivers

23. Subject has any condition that, in the opinion of the Investigator would preclude the use of the study procedure, may interfere with the evaluation of the procedure-related outcomes, or preclude the subject from completing the follow-up requirements

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Procedure:
Omental transposition for mild Alzheimers disease
An omental pedicle is brought from the abdomen underneath the skin and sewn to the dura matter of the brain via a craniotomy.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Bariatric Medicine Institute, Salt Lake City, UT

References & Publications (6)

Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004 Aug;240(2):205-13. — View Citation

Goldsmith HS, Sax DS. Omental transposition for cerebral infarction: a 13-year follow-up study. Surg Neurol. 1999 Mar;51(3):342-5; discussion 345-6. — View Citation

Goldsmith HS. Omental transposition for Alzheimer 's disease. Neurol Res. 1996 Apr;18(2):103-8. — View Citation

Goldsmith HS. Omental transposition in treatment of Alzheimer disease. J Am Coll Surg. 2007 Dec;205(6):800-4. Epub 2007 Sep 18. Review. — View Citation

Goldsmith HS. Treatment of Alzheimer's disease by transposition of the omentum. Ann N Y Acad Sci. 2002 Nov;977:454-67. — View Citation

Shankle WR, Hara J, Bjornsen L, Gade GF, Leport PC, Ali MB, Kim J, Raimo M, Reyes L, Amen D, Rudy L, O'Heany T. Omentum transposition surgery for patients with Alzheimer's disease: a case series. Neurol Res. 2008 Apr;30(3):313-25. Epub 2007 Aug 31. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of surgical complications from beginning of anesthesia to discharge from Intensive Care Unit. surgical complications will be assessed from the anesthesia start time through hospital discharge.Total incidence (%) of complications will be calculated and reported,using Clavien-Dindo Classification of Surgical Complications. Participants will be monitored for postoperative complications for the duration of their hospital stay, an expected average of 2 days. Yes
Secondary Change in Alzheimer's Disease Assessment Scale - Cognition (ADAS-cog) score from baseline at 12 months. Percentage of score change, compared to baseline 12 months No
Secondary Change in Montreal Cognitive Assessment (MoCA) score from baseline at 12 months Percentage of score change, compared to baseline 12 months No
Secondary Change in General Practitioner Assessment of Cognition (GPCOG) score from baseline at 12 months Percentage of score change, compared to baseline 12 months No
Secondary Change in Eight-item Informant Interview to Differentiate Aging and Dementia (AD8) score from baseline at 12 months Percentage of score change, compared to baseline 12 months No
Secondary Change in Alzheimer's Disease Assessment Scale - Cognition (ADAS-cog) score from baseline at 24 months Percentage of score change, compared to baseline 24 months No
Secondary Change in Montreal Cognitive Assessment (MoCA) score from baseline at 24 months Percentage of score change, compared to baseline 24 months No
Secondary Change in General Practitioner Assessment of Cognition (GPCOG) score from baseline at 24 months Percentage of score change, compared to baseline 24 months No
Secondary Change in Eight-item Informant Interview to Differentiate Aging and Dementia (AD8) score from baseline at 24 months Percentage of score change, compared to baseline 24 months No
See also
  Status Clinical Trial Phase
Completed NCT05040048 - Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
Withdrawn NCT03316898 - A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease Phase 1
Withdrawn NCT02860065 - CPC-201 Alzheimer's Disease Type Dementia: PET Study Phase 2
Completed NCT01315639 - New Biomarker for Alzheimer's Disease Diagnostic N/A
Not yet recruiting NCT03740178 - Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005) Phase 1
Recruiting NCT05607615 - A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease Phase 2
Terminated NCT03307993 - Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease Phase 1
Recruiting NCT02912936 - A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease N/A
Active, not recruiting NCT02899091 - Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease Phase 1/Phase 2
Completed NCT02907567 - Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease Phase 1/Phase 2
Not yet recruiting NCT02868905 - Identification of Epigenetic Markers Common to Obesity and Alzheimer's Disease in Women N/A
Completed NCT02580305 - SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study Phase 2
Terminated NCT02521558 - Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease N/A
Completed NCT02516046 - 18F-AV-1451 Autopsy Study Phase 3
Recruiting NCT02247180 - Cognitive Rehabilitation in Alzheimer`s Disease N/A
Completed NCT02317523 - Alzheimer's Caregiver Coping: Mental and Physical Health N/A
Completed NCT02260167 - Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol N/A
Terminated NCT02220738 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors Phase 1
Completed NCT02256306 - The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study N/A
Completed NCT02089555 - African American Alzheimer's Progression Markers - CSF and Neuro-Imaging N/A

External Links